Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide

Abstract

Drug screening on sodium currents of native myofibers by means of voltage-clamp recordings is predictive of pre-clinical anti-myotonic activity in vivo and ex vivo. By this approach we identified the N-benzylated beta-proline derivative of tocainide (To10) as the most potent use-dependent blocker of Nav1.4 so far. We tested novel analogs with modifications on the pharmacophore groups of To10. The substitution of the proline cycle with less planar piperidine or piperazine rings disclosed the importance of a two carbon atom distance and/or an additional nitrogen atom for potency. Structural changes on the xylididic group corroborated the role of a proper electronic cloud for hydrophobic interactions with the binding site. The N-benzylated moiety lead to a stereoselective behavior only in the rigid alpha-proline analog To11 vs. To10 and N-benzylated tocainide (To12). The results confirm the strict structural requirements of Nav1.4 blockers and allow to refine the drug design toward novel anti-myotonic drugs.

DOI: 10.1016/j.nmd.2011.07.001

6 Figures and Tables

05010020132014201520162017
Citations per Year

61 Citations

Semantic Scholar estimates that this publication has 61 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Luca2012SearchingFN, title={Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide}, author={Annamaria De Luca and Michela De Bellis and Filomena Corbo and Carlo Franchini and Marilena Muraglia and Alessia Catalano and Alessia Carocci and Diana Conte Camerino}, booktitle={Neuromuscular disorders : NMD}, year={2012} }